Bone Biologics closes $5M public offering, net proceeds ~$4.3M

Bone Biologics Corp

Gross proceeds $5M from 1.25M shares (or pre-funded) plus Series D/E warrants; net ~$4.3M after fees.
Series D warrants (5-year, $4 strike) and Series E warrants (18-month, $4 strike); potential $10M if fully exercised.
Proceeds to fund clinical trials, patent portfolio, and working capital.
H.C. Wainwright acted as exclusive placement agent; fees 7% of gross plus 1% management fee.
After closing, approximately 1.6M shares of common stock outstanding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.